To the full analysis
Boston Scientific stock: growth
BSXBoston Scientific reported $20.07B in revenue for fiscal 2025, up 19.9% on the prior year, up 15.2% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
5.1%
per year from 2006 to 2025, per share 4.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
4.8%
per year from 2006 to 2025, per share 4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 15.2% | 10.4% | 5.1% |
| Revenue per share | 14.1% | 9.2% | 4.3% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | 26.4% | 26.3% | 4.8% |
| Free cash flow per share | 25.3% | 25.0% | 4.0% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $7.82B | −$3.58B | $1.5B |
| 2007 | $8.36B | −$495M | $571M |
| 2008 | $8.05B | −$2.04B | $854M |
| 2009 | $8.19B | −$1.03B | $473M |
| 2010 | $7.81B | −$1.07B | $47M |
| 2011 | $7.62B | $441M | $704M |
| 2012 | $7.25B | −$4.07B | $1.03B |
| 2013 | $7.14B | −$121M | $837M |
| 2014 | $7.38B | −$119M | $1.01B |
| 2015 | $7.48B | −$239M | $353M |
| 2016 | $8.39B | $347M | $596M |
| 2017 | $9.05B | $104M | $1.11B |
| 2018 | $9.82B | $1.67B | −$6M |
| 2019 | $10.74B | $4.7B | $1.38B |
| 2020 | $9.91B | −$82M | $1.13B |
| 2021 | $11.89B | $1.04B | $1.32B |
| 2022 | $12.68B | $698M | $914M |
| 2023 | $14.24B | $1.59B | $1.7B |
| 2024 | $16.75B | $1.85B | $2.65B |
| 2025 | $20.07B | $2.89B | $3.66B |
Revenue by segment
How Boston Scientific Corporation makes its money and how that has shifted. Names are as the company reports them.
- Cardiovascular66%
- MedSurg34%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| Cardiovascular | $8.16B | $8.82B | $10.76B | $13.27B | 66.1% |
| MedSurg | $5.06B | $5.42B | $5.99B | $6.83B | 34% |
| Total revenue | $12.68B | $14.24B | $16.75B | $20.07B | 100% |
Revenue by region
Where Boston Scientific Corporation generates its revenue.
- United States64%
- Outside the US36%
Figures as a table
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| United States | $5.54B | $6.17B | $5.7B | $6.91B | $7.63B | $8.43B | $10.21B | $12.86B | 64.1% |
| Outside the US | $4.29B | $4.57B | $4.21B | $4.98B | $5.11B | $5.82B | $6.54B | $7.21B | 35.9% |
| Total revenue | $9.82B | $10.74B | $9.91B | $11.89B | $12.68B | $14.24B | $16.75B | $20.07B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Oct 2022)
- Valuation signal Fairly valued since 10 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.